Holen Sie sich die Stockscreener-App
1.42
5.33%
-0.08
Vorhandelsmarkt:
1.38
-0.04
-2.82%
Schlusskurs vom Vortag:
$1.50
Offen:
$1.5
24-Stunden-Volumen:
50,897
Relative Volume:
0.76
Marktkapitalisierung:
$6.58M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-31.88M
KGV:
-1.8933
EPS:
-0.75
Netto-Cashflow:
$-25.20M
1W Leistung:
-19.77%
1M Leistung:
-10.69%
6M Leistung:
-33.64%
1J Leistung:
-83.56%
1-Tages-Spanne:
$1.38
$1.50
1-Wochen-Bereich:
$1.38
$1.87
52-Wochen-Spanne:
$1.38
$12.53
In 8 Bio Inc Stock (INAB) Company Profile
Firmenname
In 8 Bio Inc
Sektor
Branche
Telefon
(646) 600-6438
Adresse
EMPIRE STATE BUILDING, NEW YORK
Vergleichen Sie INAB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
1.42 | 6.95M | 0 | -31.88M | -25.20M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
449.52 | 115.43B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.79 | 78.44B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
862.05 | 52.42B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.10 | 51.68B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
198.46 | 42.80B | 447.02M | -1.18B | -906.14M | -6.1812 |
In 8 Bio Inc Stock (INAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-03-18 | Eingeleitet | Laidlaw | Buy |
| 2022-08-30 | Eingeleitet | H.C. Wainwright | Buy |
In 8 Bio Inc Aktie (INAB) Neueste Nachrichten
KALA BIO (Nasdaq: KALA) details Lazar financing shift and 2026 meeting - Stock Titan
Owner RA Capital Management LP Buys 314,561 ($754.7K) Of Climb Bio Inc [CLYM] - TradingView — Track All Markets
[8-K] ImmunityBio, Inc. Reports Material Event | IBRX SEC FilingForm 8-K - Stock Titan
GRI Bio (NASDAQ: GRI) closes $8.0M offering of 10,666,667 shares, warrants - Stock Titan
GRI Bio (NASDAQ: GRI) details $6.7M equity deal and runway into Q4 2026 - Stock Titan
Layoff Tracker: Pfizer, Geron Downsize To Streamline Costs - BioSpace
GRI Bio (NASDAQ: GRI) prices $8,000,000 offering of 10,666,667 shares at $0.75 - Stock Titan
Inmune Bio Ends Sales Agreement with RBC and BTIG - TipRanks
GRI Bio, Inc. Announces Positive Phase 2a Trial Results for GRI-0621 - TradingView
GRI Bio (NASDAQ: GRI) unveils Phase 2a IPF results showing favorable safety and collagen biomarker shifts - Stock Titan
ANVS SEC FilingsAnnovis Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Chmn Hoffman Buys 45,000 ($193.8K) Of Annovis Bio Inc [ANVS] - TradingView — Track All Markets
GRI Bio Reports Positive Phase 2a Trial Results for IPF Treatment - TradingView
GRI Bio (NASDAQ: GRI) reports Phase 2a IPF topline results for GRI-0621 - Stock Titan
The 4 billion won investment quietly implemented by Yuhan four years ago returned to a "large jackpo.. - 매일경제
Pres Kalowski Sells 9,072 ($31.4K) Of Q32 Bio Inc [QTTB] - TradingView
CEO Morrison Sells 22,506 ($77.9K) Of Q32 Bio Inc [QTTB] - TradingView
NUVB SEC FilingsNuvation Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Nuvation Bio (NUVB) Chief Medical Officer reports 150K share sale and option exercise - Stock Titan
Upstream Bio (NASDAQ:UPB) Shares Down 8%Here's What Happened - MarketBeat
INMB SEC FilingsInmune Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
PALI SEC FilingsPalisade Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Palisade Bio (Nasdaq: PALI) appoints GI trials expert Izanec VP, Clinical Development - Stock Titan
Climb Bio, Inc. (CLYM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Risk Off: Will Passage Bio Inc. stock sustain high P E ratiosQuarterly Portfolio Report & Free Technical Confirmation Trade Alerts - moha.gov.vn
Officer Liu Files To Sell 10,000 Of Nuvation Bio Inc [NUVB] - TradingView
KALA BIO Form 3 shows CEO and director hold no KALA stock - Stock Titan
Can Korro Bio Inc. stock surprise with earnings upsideWeekly Profit Summary & Growth Focused Stock Pick Reports - BỘ NỘI VỤ
Nuvation Bio Inc Discontinues NUV-1511 Development - TradingView
Nuvation Bio to Participate in Upcoming Investor Conferences - Business Wire
Chmn Hoffman Buys 39,200 ($159.9K) Of Annovis Bio Inc [ANVS]-Amended - TradingView
KALA BIO, Inc. Announces Executive and Board Changes - TradingView
[8-K] KALA BIO, Inc. Reports Material Event | KALA SEC FilingForm 8-K - Stock Titan
Chmn Hoffman Buys 39,200 ($159.9K) Of Annovis Bio Inc [ANVS] - TradingView
Palisade Bio to Present at the Piper Sandler 37th Annual Healthcare Conference - GlobeNewswire
ANVS insider Form 4 shows director buying Annovis Bio stock - Stock Titan
Officer Hattersley Sells 369,051 ($2.7M) Of Nuvation Bio Inc [NUVB] - TradingView
Chmn Hoffman Buys 20,000 ($69.9K) Of Annovis Bio Inc [ANVS] - TradingView
Officer Hanley Sells 200,000 ($1.4M) Of Nuvation Bio Inc [NUVB] - TradingView
Officer Hattersley Files To Sell 369,051 Of Nuvation Bio Inc [NUVB] - TradingView
Officer Liu Files To Sell 20,000 Of Nuvation Bio Inc [NUVB] - TradingView
Nuvation Bio Surges On Ibtrozi Momentum And B. Riley Buy Rating (NYSE:NUVB) - Seeking Alpha
Officer Liu Sells 30,000 ($148K) Of Nuvation Bio Inc [NUVB] - TradingView
TELA Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference - GlobeNewswire
[Form 4] Inmune Bio, Inc. Insider Trading Activity - Stock Titan
[8-K] Inmune Bio, Inc. Reports Material Event | INMB SEC FilingForm 8-K - Stock Titan
Annovis Bio Form 4: director now holds 2,470,539 ANVS shares - Stock Titan
Nuvation Bio Inc Publishes Positive Phase 2 Study Results for Safusidenib - TradingView
[8-K] TELA Bio, Inc. Reports Material Event | TELA SEC FilingForm 8-K - Stock Titan
Korro Bio, Inc. (KRRO): RBC Capital Initiates “Sector Perform” Rating with Upside Potential - Stocks Telegraph
[8-K] Instil Bio, Inc. Reports Material Event | TIL SEC FilingForm 8-K - Stock Titan
Finanzdaten der In 8 Bio Inc-Aktie (INAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.18%
0.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):